Acceleron Pharma Inc.
BMPRII POLYPEPTIDES AND USES THEREOF

Last updated:

Abstract:

In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of bone morphogenetic protein receptor type II (BMPRII) polypeptide binds to ligands including BMP10, BMP15, activin B and BMP9 and may be used to treat fibrotic and angiogenic disorders.

Status:
Application
Type:

Utility

Filling date:

11 Feb 2020

Issue date:

7 Jan 2021